British Amern Tob Plc Sponsored Adr (BTI) Shareholder Blue Fin Capital Lowered Its Holding as Stock Value Declined; Pacira Pharmaceuticals (PCRX) Shareholder Venbio Select Advisor Decreased Its Position by $20.83 Million as Stock Declined

April 20, 2018 - By Linda Rogers

British American Tobacco p.l.c. (NYSE:BTI) Logo

Blue Fin Capital Inc decreased its stake in British Amern Tob Plc Sponsored Adr (BTI) by 46.72% based on its latest 2017Q4 regulatory filing with the SEC. Blue Fin Capital Inc sold 9,105 shares as the company’s stock declined 16.55% with the market. The institutional investor held 10,383 shares of the farming and seeds and milling company at the end of 2017Q4, valued at $696,000, down from 19,488 at the end of the previous reported quarter. Blue Fin Capital Inc who had been investing in British Amern Tob Plc Sponsored Adr for a number of months, seems to be less bullish one the $107.58 billion market cap company. The stock decreased 0.68% or $0.355 during the last trading session, reaching $51.885. About 2.54M shares traded or 18.81% up from the average. British American Tobacco p.l.c. (NYSEMKT:BTI) has declined 15.61% since April 20, 2017 and is downtrending. It has underperformed by 27.16% the S&P500.

Venbio Select Advisor Llc decreased its stake in Pacira Pharmaceuticals Inc (PCRX) by 35.3% based on its latest 2017Q4 regulatory filing with the SEC. Venbio Select Advisor Llc sold 462,888 shares as the company’s stock declined 27.90% with the market. The institutional investor held 848,572 shares of the health care company at the end of 2017Q4, valued at $38.74 million, down from 1.31 million at the end of the previous reported quarter. Venbio Select Advisor Llc who had been investing in Pacira Pharmaceuticals Inc for a number of months, seems to be less bullish one the $1.48 billion market cap company. The stock increased 2.82% or $1 during the last trading session, reaching $36.45. About 444,568 shares traded. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has declined 33.05% since April 20, 2017 and is downtrending. It has underperformed by 44.60% the S&P500.

Among 7 analysts covering British Amrcn Tobacco (NYSEMKT:BTI), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. British Amrcn Tobacco had 9 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was upgraded by Investec on Friday, August 4 to “Buy”. Societe Generale upgraded the shares of BTI in report on Friday, October 28 to “Buy” rating. The stock of British American Tobacco p.l.c. (NYSE:BTI) earned “Buy” rating by Investec on Thursday, September 8. The firm earned “Sell” rating on Thursday, December 10 by Goldman Sachs. The rating was upgraded by Morgan Stanley to “Overweight” on Wednesday, November 2. Cowen & Co initiated British American Tobacco p.l.c. (NYSE:BTI) on Tuesday, August 25 with “Market Perform” rating. As per Friday, July 29, the company rating was downgraded by Societe Generale. The firm earned “Overweight” rating on Thursday, May 25 by Piper Jaffray. Bank of America reinitiated the stock with “Buy” rating in Tuesday, August 4 report.

Among 22 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 10 have Buy rating, 1 Sell and 11 Hold. Therefore 45% are positive. Pacira Pharmaceuticals had 103 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) earned “Neutral” rating by Janney Capital on Friday, December 30. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, March 1 report. The rating was maintained by Jefferies on Thursday, March 1 with “Buy”. RBC Capital Markets maintained the shares of PCRX in report on Wednesday, October 11 with “Buy” rating. The company was maintained on Thursday, March 1 by BMO Capital Markets. The firm has “Hold” rating given on Friday, July 1 by Brean Capital. Needham downgraded the stock to “Hold” rating in Friday, February 16 report. Bank of America maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Wednesday, October 4 with “Buy” rating. The stock has “Neutral” rating by Goldman Sachs on Thursday, December 1. Needham maintained the shares of PCRX in report on Monday, September 25 with “Buy” rating.

Investors sentiment increased to 1.4 in 2017 Q4. Its up 0.01, from 1.39 in 2017Q3. It improved, as 29 investors sold PCRX shares while 41 reduced holdings. 31 funds opened positions while 67 raised stakes. 40.06 million shares or 3.76% less from 41.63 million shares in 2017Q3 were reported. Great West Life Assurance Company Can has invested 0% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Massmutual Trust Fsb Adv reported 574 shares. 1.27M are held by Macquarie Group Limited. Plante Moran Lc, Michigan-based fund reported 428 shares. Legacy Cap Prtn Incorporated has 1.14% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Td Asset Inc holds 27,300 shares. Stifel Fincl has invested 0% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). D E Shaw reported 21,900 shares stake. Employees Retirement System Of Ohio invested 0.01% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Mutual Of America Lc has invested 0.11% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Avenir Corporation stated it has 15,870 shares or 0.07% of all its holdings. Pictet Asset Mgmt stated it has 0% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Ahl Ptnrs Limited Liability Partnership holds 0% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 5,284 shares. Atlantic Trust Ltd Liability Com holds 19 shares or 0% of its portfolio. 4,300 are owned by Pacad Invest Ltd.

Analysts await Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to report earnings on May, 3. They expect $-0.15 EPS, up 60.53% or $0.23 from last year’s $-0.38 per share. After $0.18 actual EPS reported by Pacira Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -183.33% negative EPS growth.

Venbio Select Advisor Llc, which manages about $380.08 million and $1.54 billion US Long portfolio, upped its stake in Array Biopharma Inc (NASDAQ:ARRY) by 4.97 million shares to 5.47M shares, valued at $69.99 million in 2017Q4, according to the filing. It also increased its holding in Avexis Inc by 159,515 shares in the quarter, for a total of 596,217 shares, and has risen its stake in Biomarin Pharmaceutical Inc (NASDAQ:BMRN).

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts